BioCentury
ARTICLE | Product Development

CARsgen leverages investigator-led study to advance solid tumor CAR T

Durability, relapse questions remain for the Claudin18.2 program

May 11, 2022 12:13 AM UTC

Early clinical data from CARsgen’s Claudin18.2-targeting CAR T cell therapy proves that CAR T cells can shrink solid tumors, but stops short of addressing the big questions of durability and relapse in the challenging solid tumor indication.

In a paper published in Nature Medicine, CARsgen Therapeutics Holdings Ltd. (HKEX:2171) reported interim Phase I results from a Chinese investigator-initiated study of CT041 in patients with advanced gastrointestinal cancers...